Study title: Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Netland PA, Robertson SM, Sullivan EK, Silver L, Bergamini MV, Krueger S, Weiner AL, Davis AA; Travoprost Study Groups. Adv Ther. 2003 May-Jun;20(3):149-63. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Netland PA, Robertson SM, Sullivan EK, Silver L, Bergamini MV, Krueger S, Weiner AL, Davis AA; Travoprost Study Groups. Adv Ther. 2003 May-Jun;20(3):149-63.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Eye Diseases [C11] | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: TIMOLOL | |||||
| ATC code: S01ED01 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |